Guobang Pharma (SH:605507) Sou Hu Cai Jing·2025-07-30 07:33Core Insights - Guobang Pharmaceutical (605507) closed at 23.68 yuan on July 30, 2025, with a 9.99% increase and a turnover rate of 5.3% [1] - The company reported total revenue of 3.026 billion yuan for the first half of 2025, a year-on-year increase of 4.63%, and a net profit of 456 million yuan, up 12.60% year-on-year [1] Financial Performance - Total revenue for the latest reporting period was 3.026 billion yuan, reflecting a 4.63% year-on-year growth [1] - Net profit attributable to shareholders was 456 million yuan, representing a 12.60% increase year-on-year [1] - The company's non-recurring net profit was 436 million yuan, with a year-on-year growth of 10.33% [1] - Current ratio stands at 2.711, quick ratio at 2.039, and debt-to-asset ratio at 25.41% [1] Market Activity - Main capital inflow for the day was 85.0582 million yuan, accounting for 22.68% of the total transaction amount [1] - Large orders saw a net inflow of 91.0675 million yuan, making up 24.29% of the transaction amount [1] - Small orders experienced a net outflow of 36.4866 million yuan, which is 9.73% of the transaction amount [1] Company Background - Guobang Pharmaceutical Group Co., Ltd. was established in 1996 and is located in Shaoxing City, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 558.8235 million yuan and has the same amount in paid-in capital [2] - The legal representative of the company is Qiu Jiajun [2] Investment and Intellectual Property - The company has made investments in 14 enterprises and participated in 533 bidding projects [2] - It holds 4 trademark registrations and 244 patent registrations, along with 3 administrative licenses [2]